DG Comp greenlights Abbott Laboratories/St Jude Medical
The European Commission's Directorate-General for Competition yesterday cleared pharmaceutical company Abbott Laboratories’ $25 billion (€23.7 billion) acquisition of St Jude Medical, subject to the divestment of two devices used in cardiovascular treatments.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.